Clinical Research
Explore the latest developments in cellular research, including stem cell therapy, regenerative medicine, and innovative approaches to treating diseases at the cellular level.
CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
SHANGHAI, March 2, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to satricabtagene autoleucel (“satri-cel”, CT041) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction cancer (G/GEJ) in patients who have failed at least two prior lines of therapy.
Common antiparasitic drug shows promise in halting growth of aggressive skin cancer
A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers
Dr Cruz-Correa on the FDA Approval of Tislelizumab Plus Chemotherapy for Metastatic Gastric/GEJ Cancer
“I think the combination of a longer time of connectivity [between tislelizumab and] the receptor [and] the fact that [this agent] avoids the other macrophages…could have been partly responsible for the efficacy that we saw.”
Medical cannabis shows potential to fight cancer, largest-ever study finds
Analysis aims to solidify agreement on cannabis’s potential as a cancer treatment, lead author of research says
RNT Health Insights Receives Second US FDA Breakthrough Device Designation for Esophageal Cancer Detection Tool
Chandigarh [India], January 9: RNT Health Insights, a Chandigarh-based health-tech startup specializing in AI-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures, has been granted its second US FDA Breakthrough Device Designation for its Esophageal Cancer detection tool.
Detecting invasive nodules could be key to preventing unnecessary pancreatic cancer surgery
Pancreatic cysts are fluid-filled sacs that can form in the pancreas.
The Targeted Pulse: Discover the FDA’s Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers
The subcutaneous formulation of nivolumab (Opdivo Qvantig) received FDA approval for all previously approved adult solid tumor indications as monotherapy, maintenance therapy, or in combination with chemotherapy or cabozantinib (Cabometyx). Data from the phase 3 CheckMate-67T study (NCT04810078) provided support for this approval. In the trial, subcutaneous nivolumab was compared with its intravenous formulation.
FDA Grants Breakthrough Status to Endometrial Cancer Assay
The OncoSignature multiplex immunofluorescence assay received breakthrough device designation from the FDA for identifying patients with endometrial cancer who may benefit from ACR-368 (prexasertib) treatment.
MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
FRIDAY, April 18, 2025 (HealthDay News) — A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced genitourinary (GU) toxicity in patients with prostate cancer, according to a study
China’s National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
OKYO, Jan. 5, 2025 /PRNewswire/ — Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that China’s National Medical Products Administration (NMPA) has approved VYLOY™ (zolbetuximab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive.
Treatment advances across the cervical cancer spectrum – Nature Reviews Clinical Oncology
In this Review, the authors discuss key clinical trials and therapeutic advances that have informed the current treatment landscape for cervical cancers of all stages, including refinement of surgical management approaches, the establishment of chemoradiotherapy, and the integration of anti-angiogenic agents, immune-checkpoint inhibitors and antibody–drug conjugates.
Gentle electric pulses may help the body fight cancer better
Researchers at Virginia Tech have discovered that using low-intensity electric pulses on tumors might make them easier for the immune system to attack.
